Vistagen therapeutics stock.

VistaGen Therapeutics, Inc. Daily – Vickers Top Buyers & Sellers for 11/16/2023 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the …Vistagen Therapeutics, Inc. (VTGN) Stock Price, Quote, News & Analysis Save 45%! Get early access to our annual Black Friday Sale » VTGN Vistagen Therapeutics, Inc. …Vistagen therapeutics added 17% on tuesday after stifel initiated its coverage with a buy recommendation for the company's anxiety disorder drug, fasedienol. ... Webull offers Vistagen Therapeutics Inc stock information, including NASDAQ: VTGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate ...VistaGen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. Beyond our drug development expertise, we aim to improve the mental health care ecosystem with better outcomes for patients, caregivers, advocates and communities.

See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary. SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) October 6, …

VTGN stock forecast for 2023 – 2027. Last updated: September 26, 2023. VTGN. VistaGen Therapeutics, Inc. 5.30 D 0.95% (0.05)This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.

On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...Jun 30, 2023 · VISTAGEN THERAPEUTICS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in dollars, except share amounts) June 30, March 31, 2023 2023 (Unaudited) ASSETS: Current assets: Cash and cash equivalents $ 9,622,300 $ 16,637,600 Prepaid expenses and other current assets 1,889,400 802,700 5 hours ago · William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ... As of June 22, 2022, the Company had 206,640,955 shares of common stock outstanding. Conference Call VistaGen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update and discuss its financial results for its fiscal year 2022 ended March 31, 2022 .There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on VistaGen Therapeutics (VTGN – Research Repo...

William Blair initiated coverage on VistaGen Therapeutics Inc VTGN, a clinical-stage biopharmaceutical company focused on developing next-generation …

Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for ...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestigious of the three. The NASDAQ is a virtual stock exchange.Shares of VistaGen Therapeutics ( VTGN 0.15%) were jumping 15.5% higher as of 3:21 p.m. EDT on Wednesday. The big gain came after the company announced results for its fiscal year 2021 and ...On Tuesday 10/24/2023 the closing price of the VistaGen Therapeutics Inc Registered Shs share was $3.07 on NAS. Compared to the opening price on Tuesday 10/24/2023 on NAS of $2.99, this is a gain ...Dec 1, 2023 · VistaGen Therapeutics stock slips 13% after FQ1 revenue fall, bottom line miss SA News Fri, Aug. 12, 2022 2 Comments VistaGen Therapeutics GAAP EPS of -$0.10 misses by $0.02, revenue of $0.31M ... VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

This is where VistaGen Therapeutics comes into play. Shares of the penny stock were trading at $1.68 as of the closing bell on Friday. That all changed during Monday’s premarket session when VTGN stock exploded to highs of $60. VTGN Stock Catalyst. That 3,471% move was triggered by news of positive Phase 3 data.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 6, 2023-- Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced it will host a conference call and webcast on Thursday, November 9, 2023, at 2:00 p.m. Pacific Time (5: ...The U.S. Phase 1 data build on successful Phase 1 and Phase 2A clinical studies of itruvone previously conducted outside the U.S. Itruvone was well-tolerated and demonstrated a favorable safety and...Dec 1, 2023 · VTGN Earnings Date and Information. Vistagen Therapeutics last issued its quarterly earnings results on November 9th, 2023. The reported ($0.66) earnings per share for the quarter. The company earned $0.28 million during the quarter. Vistagen Therapeutics has generated $0.00 earnings per share over the last year. VistaGen Therapeutics information: analysis, Share Price, stock price history, price chart, dividends, financials, key metrics, number of shares, ...

Aug 7, 2023 · SOUTH SAN FRANCISCO, Calif., August 07, 2023--Vistagen (NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety ... 2 brokers have issued 1-year target prices for Vistagen Therapeutics' stock. Their VTGN share price targets range from $12.00 to $30.00. On average, they predict the company's share price to reach $21.00 in the next year. This suggests a possible upside of 475.3% from the stock's current price.

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; …View the latest VistaGen Therapeutics Inc. (VTGN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Sep 21, 2023 · Listed under the pharmaceutical preparations industry, VistaGen Therapeutics (NASDAQ:VTGN) focuses on developing new generation medicines for anxiety, depression and other central nervous system ... Valuation metrics show that VistaGen Therapeutics, Inc. may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of ...VistaGen Therapeutics Hype Timeline. VistaGen Therapeutics is at this time traded for 3.65. The entity has historical hype elasticity of -0.17 and average ...Fasedienol, itruvone, and VistaGen’s other pherines (PH80, PH15, and PH284) address major markets across mental health crisis to women’s health. Price Action: VTGN shares are up 13.42% at $4. ...Stock analysis for Vistagen Therapeutics Inc (VTGN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; …

Find the latest Vistagen Therapeutics, Inc. (VTGN) stock quote, history, news and other vital information to help you with your stock trading and investing.

"Phase 3 topline results due in 2H 2023." This is one of three upcoming announcements for the company. VistaGen Therapeutics inched up $0.0018 (+1.29%) to $0.14 ...Complete VistaGen Therapeutics Inc. stock information by Barron's. View real-time VTGN stock price and news, along with industry-best analysis.There are 137 funds or institutions reporting positions in VistaGen Therapeutics. This is a decrease of 34 owner (s) or 19.88% in the last quarter. Average portfolio weight of all funds dedicated ...Aug 13, 2014 · PDF Version. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/13/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a stem cell company focused on drug rescue, drug discovery and regenerative medicine, announced today that will implement a 1-for-20 reverse split of its common stock effective at the opening of trading on August 14, 2014. The Fast Track designation may expedite development of PH10 for treatment of major depressive disorder in adults SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec. 6, 2022-- Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, …Social Anxiety Disorder | Vistagen Therapeutics, Inc. Based on the 2021 National Health and Wellness Survey, social anxiety disorder (SAD) affects over 25 million Americans, with onset typically in the mid-teens or earlier, and is diagnosed slightly more frequently in females than males. SAD can be viewed as a series of acute, socially ...SOUTH SAN FRANCISCO, Calif., December 21, 2022--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with ...Vistagen common stock will begin trading. SOUTH SAN FRANCISCO, Calif., June 06, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment ...Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Find the latest Institutional Holdings data for VistaGen Therapeutics, Inc. Common Stock ... Institutional Holdings information can be used to gauge the volatility and value on the company’s stock.

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol. Product Pipeline Chart. Our CNS pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Each of our drug candidates has a differentiated potential ...Jul 22, 2022 · VistaGen Therapeutics stock is diving lower on poor results from a clinical trial.; This saw a Phase 3 study of PH94B fail to meet its primary endpoint. This has heavy trading dragging the company ... Instagram:https://instagram. copper etf stocksiphone q4lendingpoint reviews bbbdentalplans com legit View 13F filing holders of VistaGen Therapeutics Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers. 10 dollar stocklive fast gloves Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. (“Fuji”) (TSE: 4554), a pharmaceutical company specializing in development, manufacture and … fpe etf Cerevel's stock doubled to $25.20 a share after the company put out the data in a press release. ... recently initiated coverage of VistaGen Therapeutics and pegged the company as a hidden gem.Track VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors As of August 10, 2023, the Company had 9,362,444 shares of common stock outstanding. Conference Call. Vistagen will host a conference call and live audio webcast this afternoon at 4:30 p.m. Eastern Time to provide a corporate update. U.S. Dial-in ... VISTAGEN THERAPEUTICS, INC.